Sixty-seven patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated with CD19-CART and enrolled in the study, of which 33 patients received Tocilizumab. This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.